The potential impact of gilteritinib in patients with FLT3-ITD AML?

The potential impact of gilteritinib in patients with FLT3-ITD AML?

User Photo
obr

2 years
149 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients with FLT3-ITD acute myeloid leukemia (AML)
Up Next Autoplay